Alcon Inc. - Registered Shares

Alcon Inc. - Registered Shares

ALC

Market Cap$45.24B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Alcon Inc. - Registered SharesAlcon Inc. - Registered Shares43.20.27%-4.8-

Earnings Call Q5 2023

February 28, 2024 - AI Summary

Alcon reported strong fourth quarter sales of $2.3 billion, up 10% year-over-year, driven by growth in both the Surgical and Vision Care franchises.
The company expects net sales for 2024 to be between $9.9 billion and $10.1 billion, representing constant currency growth of 6% to 8%. This is underpinned by a robust product portfolio and anticipated market growth.
Alcon plans to launch UNITY VCS, its next-generation Phacovit device, which is expected to drive upgrades and capture market share. FDA authorization is expected in the coming months, with international markets following in early 2025.

Exclusive for Stockcircle Pro members

Sign upSign Up
$100.00

Target Price by Analysts

9% upsideAlcon - Registered Shares Target Price DetailsTarget Price
$13.18

Current Fair Value

85.6% downside

Overvalued by 85.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$45.24 Billion
Enterprise Value-
Dividend Yield$0.24 (0.27%)
Earnings per Share$2.11
Beta0.92
Outstanding Shares499,700,000
Avg 30 Day Volume727,800

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio43.17
PEG101.51
Price to Sales4.83
Price to Book Ratio-
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income0
Total Debt to Enterprise-
Debt to Equity-

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Alcon, Inc.

20,000 employees
CEO: David J. Endicott

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the followi...